[Anti-angiogenesis treatment for brain tumors--present and future].
Takano
Shingo
S
Department of Neurosurgery, Institute of Clinical Medicine, Graduate School of Comprehensive Human Science, University of Tsukuba.
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003864:Depression, Chemical; D005346:Fibroblast Growth Factors / Q000378:metabolism; D005910:Glioma / Q000098:blood supply* / Q000188:drug therapy*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use; D045726:Metalloproteases / Q000037:antagonists & inhibitors; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D012176:Retinoids / Q000494:pharmacology / Q000627:therapeutic use; D013498:Suramin / Q000494:pharmacology / Q000627:therapeutic use; D013792:Thalidomide / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D006877:Hydroxamic Acids; D017468:Receptors, Fibroblast Growth Factor; D012176:Retinoids; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D013792:Thalidomide; D013498:Suramin; D005346:Fibroblast Growth Factors; C100342:marimastat; D040262:Receptors, Vascular Endothelial Growth Factor; D045726:Metalloproteases